Rational Design of Antiangiogenic Helical Oligopeptides Targeting the Vascular Endothelial Growth Factor Receptors

Area of Science:

• Biochemistry
• Molecular Biology
• Medicinal Chemistry

Background:

• Tumor angiogenesis, crucial for cancer growth, is primarily regulated by vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs).
• The interaction between VEGF and VEGFR is a significant pharmaceutical target for inhibiting cancer progression.

Purpose of the Study:

• To rationally design and synthesize helical oligopeptides that mimic the VEGF-C alpha-helix.
• To stabilize the helical conformation of these peptides for enhanced therapeutic potential.
• To evaluate the antiangiogenic activity and receptor binding properties of the designed peptides.

Main Methods:

• Structural analysis and computational studies guided the rational design of helical peptides.
• Introduction of helix-inducing Cα,α-disubstituted amino acids and optimization of intramolecular interactions stabilized peptide conformation.
• Circular dichroism and nuclear magnetic resonance characterized peptide conformation.
• In vitro assays determined receptor binding affinity and antiangiogenic efficacy.

Main Results:

• Designed helical peptides successfully mimicked the VEGF-C helix structure.
• The synthetic peptides demonstrated conformational stability.
• The most effective peptides exhibited potent in vitro antiangiogenic activity at nanomolar concentrations.
• These lead peptides showed resistance to proteolytic degradation, enhancing their therapeutic viability.

Conclusions:

• Rational design of helical peptides targeting the VEGF/VEGFR interaction is a viable strategy for developing antiangiogenic cancer therapies.
• The developed peptides possess promising characteristics, including high potency and stability, for further investigation as anti-cancer agents.